These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 38592590)

  • 1. Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer.
    Grisay G; Lavaud P; Fizazi K
    Curr Oncol Rep; 2024 May; 26(5):488-495. PubMed ID: 38592590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis.
    Ciccarese C; Iacovelli R; Sternberg CN; Gillessen S; Tortora G; Fizazi K
    Eur J Cancer; 2022 Sep; 173():276-284. PubMed ID: 35964470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review.
    Hussain M; Fizazi K; Shore ND; Heidegger I; Smith MR; Tombal B; Saad F
    JAMA Oncol; 2024 Jun; 10(6):807-820. PubMed ID: 38722620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
    Yanagisawa T; Rajwa P; Kawada T; Mori K; Fukuokaya W; Petrov P; Quhal F; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pradere B; Kramer G; Kimura T; Shariat SF
    J Urol; 2023 Sep; 210(3):416-429. PubMed ID: 37339479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective?
    Sathianathen NJ; Lawrentschuk N; Konety B; Azad AA; Corcoran NM; Bolton DM; Murphy DG
    Eur Urol Oncol; 2024 Aug; 7(4):870-876. PubMed ID: 38057191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis.
    Fiorica F; Buttigliero C; Grigolato D; Muraro M; Turco F; Munoz F; Tucci M
    Curr Oncol; 2022 Dec; 29(12):9511-9524. PubMed ID: 36547161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Real World Observational Study Characterizing Patients With Advanced Prostate Cancer Treated With or Without Androgen Receptor-Pathway-Inhibitor Therapies in Alberta, Canada.
    O'Sullivan DE; Kolinsky MP; Shokar S; Jarada TN; Cheung WY
    Clin Genitourin Cancer; 2024 Oct; 22(5):102115. PubMed ID: 38890099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
    Fizazi K; Foulon S; Carles J; Roubaud G; McDermott R; Fléchon A; Tombal B; Supiot S; Berthold D; Ronchin P; Kacso G; Gravis G; Calabro F; Berdah JF; Hasbini A; Silva M; Thiery-Vuillemin A; Latorzeff I; Mourey L; Laguerre B; Abadie-Lacourtoisie S; Martin E; El Kouri C; Escande A; Rosello A; Magne N; Schlurmann F; Priou F; Chand-Fouche ME; Freixa SV; Jamaluddin M; Rieger I; Bossi A;
    Lancet; 2022 Apr; 399(10336):1695-1707. PubMed ID: 35405085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis.
    Wang T; Wang X; Ding G; Liu H; Ma X; Ma J; Cui Y; Wu J
    Br J Cancer; 2024 Nov; 131(8):1363-1377. PubMed ID: 39223303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.
    Narita S; Kimura T; Hatakeyama S; Hata K; Yanagisawa T; Maita S; Chiba S; Sato H; Kashima S; Koizumi A; Yamamoto R; Takayama K; Okane K; Ishida T; Horikawa Y; Kumazawa T; Shimoda J; Suzuki T; Ohyama C; Egawa S; Nomura K; Habuchi T
    World J Urol; 2022 May; 40(5):1135-1141. PubMed ID: 35218371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status and future perspective on the management of metastatic castration-sensitive prostate cancer.
    Blas L; Shiota M; Eto M
    Cancer Treat Res Commun; 2022; 32():100606. PubMed ID: 35835707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S; Lang JM; Jarrard DF
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: An updated systematic review and network meta-analysis.
    Sathianathen NJ; Pan HYC; Lawrentschuk N; Siva S; Azad AA; Tran B; Bolton D; Murphy DG
    Urol Oncol; 2023 May; 41(5):233-239. PubMed ID: 36411180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.
    Swami U; Graf RP; Nussenzveig RH; Fisher V; Tukachinsky H; Schrock AB; Li G; Ross JS; Sayegh N; Tripathi N; Mathew Thomas V; Oxnard GR; Antonarakis ES; Agarwal N
    Clin Cancer Res; 2022 Nov; 28(22):4917-4925. PubMed ID: 36088616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)-A Potential New Standard of Care.
    Mittal A; Sridhar SS; Ong M; Jiang DM
    Curr Oncol; 2023 Apr; 30(4):4365-4378. PubMed ID: 37185445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
    Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
    Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of metastatic hormone-sensitive prostate cancer: from doublet therapy to triplet therapy.
    Ye SJ; Huang RD; Fei X; Tao ZL; Liu WH; Ma Q
    Postgrad Med J; 2024 Sep; 100(1188):703-708. PubMed ID: 38767468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.